STOCK TITAN
  1. Home
  2. Sec-filings
  3. CTNM
  4. [Form 4] Contineum Therapeutics, Inc. Insider Trading Activity

Contineum Therapeutics Issues Routine Board Option Grant, No Share Sales

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) – Form 4 insider transaction filed 06/26/2025

Director Todd R. Brady reported the grant of a non-qualified stock option covering 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular Non-Employee Director Compensation Program.

Key terms

  • Grant date: 26 Jun 2025
  • Vesting: 100 % on the earlier of 26 Jun 2026 (one-year anniversary) or the next annual stockholders’ meeting, contingent on continuous board service
  • Expiration: 25 Jun 2035 (10-year term)
  • Form of ownership: Direct
  • No open-market purchases or sales of common shares were reported in Table I

The filing increases Brady’s reported derivative holdings to 14,750 options; no changes were disclosed for non-derivative share ownership. The transaction is routine board compensation and does not affect the company’s share count, cash position, or operating fundamentals. Investors should view it primarily as a standard alignment mechanism between the director and shareholders rather than a catalyst for valuation change.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine option grant to CTNM director; neutral impact on valuation, minor signal of continued board engagement.

The filing documents a standard annual equity award under CTNM’s director compensation policy. The option covers 14,750 shares—immaterial versus CTNM’s public float—so dilution risk is negligible. Because the award vests fully within a year (or at the next AGM) and carries a 10-year life at $4.01 strike, it incentivises long-term oversight without imposing near-term cash costs. There is no accompanying share sale, which avoids negative signalling. From a governance angle, the structure is conventional and shareholder-friendly. Given the absence of operational data or market-moving information, the disclosure is best characterised as neutral; investors should not expect material price reaction.

Insider Brady Todd R.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 14,750 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 14,750 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brady Todd R.
(Last) (First) (Middle)
3565 GENERAL ATOMICS COURT, SUITE 200
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $4.01 06/26/2025 A 14,750 (1) 06/25/2035 Class A Common Stock 14,750 $0 14,750 D
Explanation of Responses:
1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
/s/ Peter Slover, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CTNM report on 26 June 2025?

CTNM disclosed a grant of 14,750 stock options to director Todd R. Brady at a $4.01 exercise price.

Does the filing involve any sale of Contineum Therapeutics common stock?

No. The Form 4 only reports an option grant; no shares were bought or sold.

When will the new CTNM options vest?

They vest in full on the earlier of 26 Jun 2026 or the next annual stockholders’ meeting, subject to continued board service.

What is the expiration date of the options granted to Todd Brady?

The options expire on 25 June 2035, giving a 10-year exercise window.

How many derivative securities does the director now beneficially own?

Following the grant, Brady reports owning 14,750 stock options in Contineum Therapeutics.